| abstract |
(3a alpha, 4 beta, 7a alpha) -hexahydro-2- [4[4-(2-pyrimidinyl) -1- (piperazinyl) -butyl]-4, 7-methylene-1H-isoindole-1, 3(2H) -dione citrate monohydrate, and a preparation method and use thereof. The (3a alpha, 4 beta, 7a alpha) -hexahydro-2- [4[4- (2-pyrimidinyl) -1- (piperazinyl) -butyl]-4, 7-methylene-1H-isoindole-1, 3(2H) -dione citrate monohydrate having the formula C 21 H 29 N 5 O 2 ·C 6 H 8 O 7 ·H 2 And O. The new crystal improves the solubility and stability of the existing product, is beneficial to the preparation and use of the product, and improves the safety and effectiveness of the medicine. |